Reproducibility of histological subtyping of malignant pleural mesothelioma by Brčić, Luka et al.
  
    
 
Središnja medicinska knjižnica 
 
 
 
Brčić L., Jakopović M., Brčić I., Klarić V., Milošević M., Šepac A., 
Samaržija M., Seiwerth S. (2014) Reproducibility of histological 
subtyping of malignant pleural mesothelioma. Virchows Archiv, 456 
(6). pp. 679-85. ISSN 0945-6317 
 
 
http://www.springer.com/journal/428 
 
http:// link.springer.com/journal/428 
 
 
The final publication is available at Springer via 
http://dx.doi.org/10.1007/s00428-014-1664-9 
 
 
 
http://medlib.mef.hr/2375 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
 
 
 
 
 1 
Reproducibility of histological subtyping of malignant pleural 
mesothelioma 
Luka Brčić,1, 2 Marko Jakopović,3 Iva Brčić,2 Vlasta Klarić,1 Milan Milošević,4 
Ana Šepac,1 Miroslav Samaržija,3 Sven Seiwerth1, 2 
1
Institute of Pathology, University of Zagreb School of Medicine, Zagreb, Croatia 
2
Clinical Department of Pathology and Cytology, University Hospital Centre Zagreb, 
Zagreb, Croatia 
3
University of Zagreb School of Medicine, Department for Respiratory Diseases 
Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia 
4
University of Zagreb School of Medicine, Andrija Stampar School of Public Health, 
Department for Occupational and Occupational Health, Zagreb, Croatia 
Corresponding author: Luka Brcic, University of Zagreb School of Medicine Institute of 
Pathology, Salata 10, 10000 Zagreb, Croatia. Tel: +385 91 3693693; fax: +385 1 4921151; 
email: lbrcic@mef.hr  
 
 2 
Abstract 
Malignant pleural mesothelioma (MPM) has a very poor prognosis. Although clinical stage 
is currently the only reliable prognostic factor, histologic subtyping reportedly also affects 
prognosis. Some studies propose reclassification of pleomorphic epithelioid as biphasic or 
sarcomatoid MPM. This study assessed prognostic significance and interobserver 
agreement in MPM subtyping of small biopsy specimens. We analyzed biopsy specimens, 
clinical and survival data from records of 108 patients who were diagnosed between 2000 
and 2010 at the Institute of Pathology University of Zagreb School of Medicine, of whom 
98 had epithelioid MPM, 6 biphasic MPM and 4 sarcomatoid MPM. Among epithelioid 
subtypes, 44 (44.9%) were solid, 19 (19.4%) tubulopapillary, 18 (18.4%) acinar, 6 (6.1%) 
adenomatoid, 5 (5.1%) pleomorphic, 4 (4.1%) trabecular and 2 (2.0%) micropapillary 
subtype. Interobserver reliability for histological diagnosis was found to be κ = 0.72 
(P < 0.001). Median overall survival for epithelioid MPM was 10.5 months with an 
interquartile range (IQR) of 5.8–28.0 months, but significantly shorter for the pleomorphic 
subtype (3 [IQR 3.0–8.0] months; P = 0.034), but not significantly different from biphasic 
(6.5 [IQR 3.5–15.3] months) and sarcomatoid mesothelioma (4.0 [IQR 1.3–6.8] months; 
P = 0.270). We found strong reproducibility of MPM subtyping with good interobserver 
agreement. Furthermore, our results indicate that pleomorphic subtype to be a predictor of 
poor prognosis, and support classifying it with sarcomatoid or biphasic MPM, as patients 
with the pleomorphic, biphasic or sarcomatoid subtype show similarly poor overall 
survival. 
Key words: malignant pleural mesothelioma subtyping, epithelioid mesothelioma, 
pleomorphic mesothelioma, survival, prognostic factor. 
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Introduction 
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer that develops from 
mesothelial cells. MPM is most commonly caused by exposure to asbestos fibers; because 
of its long latency period, its increasing incidence is expected to peak in this decade, at 
least for developed countries [1]. Although MPM is the most common primary pleural 
malignancy, it is rather difficult to diagnose [2].
 
It is still incurable, with median survival 
after symptom onset of up to 12 months, despite advances in multimodality protocols [3–
5]. A small number of patients have reportedly survived longer than 5 years [6, 7]. 
Management of patients with MPM should be based on prognostic factors with more 
aggressive therapy, for example, applied to patients who are expected to survive longer. 
Histology and TNM staging show the highest prognostic significance although these 
classifications are rather robust and not precise [8].
 
The current 2004 World Health Organization classification of pleural tumors [9] recognizes 
three main histological types of mesothelioma, epithelioid (accounting for 50–60%), 
biphasic (25–35%) and sarcomatoid (10–20%) [10]; however, even within single 
histological types, MPM is very heterogeneous with various histological patterns, 
especially in the epithelioid type. The importance of histological subtyping lies in their 
significant bearing on survival, with epithelioid having the best prognosis [11], whereas the 
pleomorphic subtype and sarcomatoid MPMs both reportedly have similarly poor 
outcomes [12]. The 2012 Update of the Consensus Statement from the International 
Mesothelioma Interest Group recommended that MPM diagnoses include subtype if 
possible, with histological pattern in the description [13]. So far, only Kadota et al have 
comprehensively subtyped epithelioid mesothelioma and correlated its clinicopathological 
characteristics and prognosis, mainly using extrapleural pneumectomy and pleurectomy 
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decortication samples; their study suggested reclassifying pleomorphic epithelioid 
mesothelioma as a biphasic or sarcomatoid type based on its very poor survival [11], which 
accords with an earlier study by Ordonez who analyzed 10 pleomorphic mesotheliomas 
[12].
 
This study assessed interobserver agreement in subtyping of MPM using small biopsy 
specimens, and prognostic significance of subtypes.  
Materials and Methods 
We identified 135 patients who were diagnosed with MPM between 2000 and 2010 at the 
Institute of Pathology University of Zagreb School of Medicine, using the Institute’s 
records and specimen archives; and extracted each patient’s age, sex, asbestos exposure, 
laterality, presence of pleural effusion, diagnostic procedure, TNM stage, and treatment 
from the database of the Clinic for Lung Diseases Jordanovac, University Hospital Centre 
Zagreb, and from the Croatian National Cancer Registry. Patients were restaged according 
to the seventh AJCC, using mainly computed tomography (CT) and, more recently, 
positron emission tomography (PET). We ascertained patients’ survival data as of 
23
 
August 2013. This study was approved by our institutional review board. 
Pathologic diagnosis was based on hematoxylin–eosin (HE)-stained slides and 
immunohistochemistry, using at least two positive markers of calretinin, CK 5/6, WT-1, 
and thrombomodulin, and at least two negative markers for adenocarcinoma 
(carcinoembryonic antigen, thyroid transcription factor-1 and CD15). 
All HE-stained slides were reviewed independently by two pathologists (L.B. and S.S.) and 
classified as epithelioid, sarcomatoid or biphasic type, according to the 2004 WHO 
classification criteria for pleural tumors [9], and used a median of 3 slides per case (range: 
1–16). Epithelioid MPM were further subtyped according to their predominant patterns as 
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acinar, adenomatoid (microglandular), micropapillary, solid, tubulopapillary, and trabecular 
as defined previously [11, 13, 14] (Fig. 1 and 2). Slides were reviewed individually by each 
pathologist but were reviewed together to reach a consensus in cases of disagreement. 
Myxoid changes in stroma were evaluated in all samples, and regarded as positive if they 
occupied more than 50% of a tumor sample [15].
 
Statistical analysis 
For all patients, potential prognostic factors were measured at the time of diagnosis and 
evaluated as categorical variables. Differences in survival time between histology groups 
were assessed with Kruskal–Wallis test with corresponding Mann–Whitney U test for post-
hoc analyses. For OS analysis, Kaplan–Meier curves were compared using log-rank test. 
All patients still alive at the last follow-up were censored. The Cox proportional hazards 
regression model was used for multivariate analysis. We calculated hazard ratios and 95% 
confidence intervals. We analyzed interobserver reliability using the κ statistic to determine 
consistency between pathologists. P < 0.05 was considered significant. All analyses used 
IBM SPSS Statistics 21.0 (www.spss.com; SPSS Inc., USA). 
Results 
Patients’ demographic and clinicopathological data are summarized in Table 1. Out of the 
initial 135 patients, we included 108 patients who had microscopically confirmed 
diagnoses of mesothelioma and complete clinical information. Their median age for all 
types was 63 (interquartile range; IQR 54–69) years; most patients (65/108, 60.2%) were 
65 years or younger. Of the 108 patients, 86.1 % (93/108) were male; 37.9% (41/108) had 
histories of occupational exposure to asbestos, although this data was not available for all 
patients; 63.9% (69/108) had tumors in their right lungs; 71.3% (77/108) had pleural 
effusion; 4.6% (5/108) had stage II disease, 24.1% (26/108) had stage III disease and 
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71.3% (77/108) had stage IV disease, but none had stage I disease. Some 60.2% (65/108) 
of patients were diagnosed by video-assisted thoracoscopic surgery; 32.4% (35/108) 
underwent open biopsy and 7.4% (8/108) had percutaneous pleural biopsy. Only 13% 
(14/108) underwent palliative surgery, of which 92.9% (13/14) were pleurectomy 
decortications and one (7.1%; 1/14) was an extrapleural pneumonectomy.  
We found 90.7% (98/108) of specimens were epithelioid, 5.6% (6/108) biphasic and 3.7% 
(4/108) sarcomatoid MPM. Among the 98 epithelioid-type specimens, 44.9% (44/98) were 
solid, 19.4% (19/98) tubulopapillary, 18.4% (18/98) acinar, 6.1% (6/98) adenomatoid, 
5.1% (5/98) pleomorphic, 4.1% (4/98) trabecular and 2.0% (2/98) micropapillary subtypes 
(Figure 3). Interobserver reliability for the 2 pathologist was found to be κ=0.72 
(P < 0.001). 
Median overall survival (OS) for epithelioid type was 10.5 months (IQR 5.8–28.0 months), 
whereas the pleomorphic subtype had a significantly shorter OS (median 3 [IQR 3.0–8.0] 
months, P = 0.034), that was not significant different from those of the biphasic (6.5 [IQR 
3.5–15.3] months) and sarcomatoid subtypes (4.0 [IQR 1.3–6.8] months; P = 0.270). 
Patients’ ages did not significantly differ among the different subtypes of epithelioid MPM 
or in comparison to the sarcomatoid and biphasic types.  
Among epithelioid subtypes, the pleomorphic subtype was associated with significantly 
shorter OS (median 3 months [IQR 3.0–8.0], P = 0.034). The adenomatoid and 
tubulopapillary subtypes had the longest OS (median 25.5 months each), followed by 
acinar (median OS 13 [IQR 5.8–29.3] months), trabecular and micropapillary (median OS 
11 months each), and solid subtypes (median OS 8.5 months). Cox’s proportional hazards 
regression models proved pleomorphic subtype to be a significant predictor for shorter OS 
(Table 2). Compared with the pleomorphic subtype, decreased risk of death by subtype was 
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adenomatoid: 81.5%; tubulopapillary: 80.3%; acinar: 73.2%; solid: 72.9%; trabecular: 
61.5%; and micropapillary: 58.9%. Bivariate and multivariate analyses showed age, sex, 
pleural effusion, laterality, surgery type, myxoid stroma and asbestos exposure had no 
prognostic significance. Moreover, the log-rank test showed that OS among patients with 
the pleomorphic subtype did not significantly differ from those with biphasic or 
sarcomatoid subtypes (P = 0.270; Figure 4). 
Discussion 
We reviewed MPM specimens from the archives of the Institute of Pathology, University 
of Zagreb School of Medicine to evaluate interobserver agreement in subtyping small 
biopsy samples, and to evaluate the prognostic significance of subtyping.  
Older age, higher clinical stage and non-epithelioid histological type have been associated 
with shorter survival (review by Pass [16]). The 2012 Update of the Consensus Statement 
from the International Mesothelioma Interest Group guidelines recognized difficulties with 
pattern recognition in small biopsies, and recommended using three main histological types 
(epithelioid, sarcomatoid, biphasic) with pattern descriptions in medical records, if possible 
[13]. Histological subtyping/patterns in many carcinomas correlate with patients’ 
clinicopathological characteristics [17–22]. A reclassification proposal for resectioned lung 
adenocarcinoma specimens has even proposed reporting different patterns by 5% 
increments, based on predominant histology, as these patterns closely correlate to 
molecular and genetic characteristics and, more importantly, prognosis [23].  
The idea of similar correlation in MPM patients is very appealing, especially for centers 
that do not routinely perform extrapleural pneumonectomies and pleurectomy 
decortications, and relevant specimens are not abundant. Histopathological typing for 
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MPM is apparently influenced by the size of tissue sample [24] and those from complete 
surgical resection may differ from initial diagnostic biopsies [25].  
For the purpose of our study we used tubulopapillary, adenomatoid (also called 
microglandular), solid, acinar, micropapillary, trabecular and pleomorphic subtypes (the 
latter as defined in the 2004 WHO guidelines) [9]. We found that micropapillary, trabecular 
and pleomorphic subtypes are relatively few, accounting for only 2%, 4.1% and 5.1% of 
MPMs, respectively.  
This scarcity demonstrates a limitation of our study: the small subject groups for some 
subtypes. It may also reflect a problem with smaller specimens. Most our samples were 
obtained using VATS and open biopsy, with a median of 3 slides reviewed per case (range: 
1–16). In contrast, almost 90% of samples in the study by Kadota K. et al [11] were 
diagnosed on much larger extrapleural pneumonectomy and pleurectomy decortication 
specimens, resulting in significantly more reviewed slides per patient (median: 9 slides, 
range: 1–43). The very small size of the most of our samples occasionally made subtyping 
difficult, although interobserver reliability showed substantial agreement.  
Because of these small numbers for specific subtypes, some of our statistical results should 
be viewed cautiously. With that caveat, our results indicate that the very poor OS for the 
pleomorphic subtype of epithelioid MPM is statistically indistinguishable from biphasic 
and sarcomatoid types of MPM. The sarcomatoid type has the worst prognosis and is a 
negative predictive factor for chemotherapy and radiotherapy. To our knowledge, only one 
large study, by Kadota et al [11] has demonstrated that subtypes within the epithelioid 
classification had significant prognostic importance; the Kadota study suggested that the 
pleomorphic subtype be reclassified as biphasic or sarcomatoid, based on their similarly 
poor outcomes. Ordonez also showed pleomorphic epithelioid MPM to be an adverse 
 9 
prognostic factor in a 10-patient series [12]. Another study, by Galateau-Salle et al., 
reported shorter median survival of pleomorphic MPM (7 months) compared with non-
pleomorphic MPM (14 months) [26]. However, some authors found no clinical variations 
among different histological patterns [14].
 
Our OS hazard ratios should be interpreted only to indicate that the pleomorphic subtype is 
a negative predictor, whereas the other values indicate tendencies only for each group; for 
more definitive results, much larger groups of each subtype are needed. Our results might 
differ from those of Kadota et al [11] for this reason, especially for the micropapillary 
group which only included 2 patients in our population.  
Our findings demonstrate that histological subtyping can be performed even in small 
samples without abundant tumor tissue, with strong interobserver agreement, and clear 
prognostic implications. We strongly feel that subtypes such as acinar or adenomatoid 
should be retained, as we need much more data on each pattern to see their real prognostic 
significance, which could be obscured by fewer groupings. Although our findings should 
be interpreted with caution because of the few subjects with certain MPM subtypes, we do 
support the line that the pleomorphic subtype of epithelioid MPM should be reclassified as 
a sarcomatoid or biphasic subtype, based on overall survival. 
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Figure legends 
 
Fig. 1  Histological presentation of epithelioid malignant pleural mesothelioma subtypes. 
a: acinar; b: adenomatoid; c: trabecular (hematoxylin–eosin staining; magnification: ×10 [a 
and b], ×20 [c]) 
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Fig. 2  Histological presentation of epithelioid malignant pleural mesothelioma subtypes. 
a: micropapillary; b: tubulopapillary; c: solid; d: pleomorphic (hematoxylin–eosin staining; 
magnification: ×10 [a and b], ×20 [c]) 
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Fig. 3  Distribution of different histological subtypes of malignant pleural mesothelioma in 
our study group 
 
 
 
 
 
 
 
 
 18 
Fig. 4  Overall survival comparison between epithelioid, pleomorphic, biphasic and 
sarcomatoid MPM using Kaplan–Meier method showed that the latter three types did not 
significant differ in overall survival, but they each significantly differed from that of the 
epithelioid type 
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Table 1. Summary of clinical characteristics in 108 patients with MPM 
 Number % 
All patients 108 100 
Median age, yrs (IQR
a
) 63 (54–69) 
Sex 
Female  15 13.9 
Male 93 86.1 
Side of disease 
Right 69 63.9 
Left 39 36.1 
Asbestos exposure 
No 19 17.6 
Yes 41 38.0 
Unknown 48 44.4 
Pleural effusion 
No 31 28.7 
Yes 77 71.3 
Method of diagnosis 
VATS
b 
65 60.2 
Open biopsy 35 32.4 
Percutaneous pleural 
biopsy 8 7.4 
Clinical stage 
1 0 0 
2 5 4.6 
3 26 24.1 
4 77 71.3 
Pleurodesis 
No 57 52.8 
Yes 51 47.2 
Treatment 
None 34 31.5 
Gemcitabine-based 19 17.6 
Pemetrexed-based 10 9.3 
Others 25 23.1 
Unknown 20 18.5 
a
Interquartile range 
b
Video-assisted thoracoscopic surgery 
 20 
Table 2. Hazard ratios calculated for significant determinants of survival using Cox 
proportional hazard model 
  P OR 95% CI 
Histology    
Pleomorphic 
a
 0.006   
Acinar 0.004 0.20 0.07–0.59 
Adenomatoid 0.005 0.16 0.04–0.56 
Micropapillary 0.266 0.38 0.07–2.07 
Solid 0.007 0.25 0.09–0.68 
Tubulopapillary <0.001 0.14 0.05–0.41 
Trabecular 0.069 0.28 0.07–1.11 
Biphasic 0.209 0.45 0.13–1.56 
Sarcomatoid 0.949 1.05 0.26–4.15 
Age (years) 0.430 1.01 0.99–1.03 
Male sex 0.764 0.91 0.50–1.66 
Surgical procedure 0.630 1.19 0.58–2.44 
Clinical stage 0.327 1.24 0.81–1.90 
Right vs. left side 0.167 0.72 0.46–1.14 
a 
Reference subtype 
Bolded values are statistically significant (P < 0.05) 
 
 
